Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.

Citation data:

Oncotarget, ISSN: 1949-2553, Vol: 6, Issue: 7, Page: 4663-76

Publication Year:
2015
Usage 367
Downloads 230
Abstract Views 136
Full Text Views 1
Captures 66
Readers 66
Social Media 7
Tweets 7
Citations 18
Citation Indexes 18
Repository URL:
https://escholarship.umassmed.edu/thompson/102
PMID:
25609199; 28038441; 26440311
DOI:
10.18632/oncotarget.3081; 10.18632/oncotarget.14247; 10.18632/oncotarget.5937
PMCID:
PMC4467106; PMC4742161
Author(s):
Schölch, Sebastian; Rauber, Conrad; Tietz, Alexandra; Rahbari, Nuh N; Bork, Ulrich; Schmidt, Thomas; Kahlert, Christoph; Haberkorn, Uwe; Tomai, Mark A; Lipson, Kenneth E; Carretero, Rafael; Weitz, Jürgen; Koch, Moritz; Huber, Peter E Show More Hide
Publisher(s):
Impact Journals, LLC
Tags:
Medicine; cancer prevention; colorectal cancer; epigenetics; microRNA; protein arginine deiminases; Biochemistry; Digestive System Diseases; Enzymes and Coenzymes; Medicinal-Pharmaceutical Chemistry; Neoplasms; Therapeutics
Most Recent Tweet View All Tweets
article description
In addition to local cytotoxic activity, radiotherapy may also elicit local and systemic antitumor immunity, which may be augmented by immunotherapeutic agents including Toll-like receptor (TLR) 7/8 agonists. Here, we investigated the ability of 3M-011 (854A), a TLR7/8 agonist, to boost the antigen-presenting activity of dendritic cells (DC) as an adjuvant to radiotherapy. The combined treatment induced marked local and systemic responses in subcutaneous and orthotopic mouse models of colorectal and pancreatic cancer. In vitro cytotoxicity assays as well as in vivo depletion experiments with monoclonal antibodies identified NK and CD8 T cells as the cell populations mediating the cytotoxic effects of the treatment, while in vivo depletion of CD11c+ dendritic cells (DC) in CD11c-DTR transgenic mice revealed DC as the pivotal immune hub in this setting. The specificity of the immune reaction was confirmed by ELISPOT assays. TLR7/8 agonists therefore seem to be potent adjuvants to radiotherapy, inducing strong local and profound systemic immune responses to tumor antigens released by conventional therapy.